Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q9BSY9

UPID:
DESI2_HUMAN

ALTERNATIVE NAMES:
Desumoylating isopeptidase 2; PPPDE peptidase domain-containing protein 1; Protein FAM152A

ALTERNATIVE UPACC:
Q9BSY9; B1APK6; Q5VVC6; Q9NYS2; Q9Y3E4

BACKGROUND:
The protein Deubiquitinase DESI2, known under various names such as Desumoylating isopeptidase 2 and PPPDE peptidase domain-containing protein 1, plays a pivotal role in the deubiquitination of 'Lys-48'- and 'Lys-63'-linked polyubiquitin chains. This activity is essential for the stabilization of RPS7, indicating its significance in maintaining protein equilibrium within the cell.

THERAPEUTIC SIGNIFICANCE:
The exploration of Deubiquitinase DESI2's function offers a promising avenue for the development of novel therapeutic approaches. Its critical involvement in protein deubiquitination and stabilization highlights its potential as a target in therapeutic strategy formulation.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.